Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMAfore
2020-003969-19Phase 3Active
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Novartis. Primary endpoint: Radiographic progression-free survival. Started Jan 2021; status: active.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2020-003969-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003969-19.